StockData
BioXcel Therapeutics, Inc. logo

BioXcel Therapeutics, Inc. (BTAIQ) stock

BTAIQOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 3/30
$0.03−0.00 (-13.49%)

Close on Oct 19, 2026Market cap $757.50KP/E –Yield –

BioXcel Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

BioXcel Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$50.90M. For fiscal 2025 it was -$57.62M. The highest annual figure on record is -$2.20M in fiscal 2017.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$57.62M–
FY2024Dec 31, 2024-$72.03M–
FY2023Dec 31, 2023-$155.01M–
FY2022Dec 31, 2022-$135.34M–
FY2021Dec 31, 2021-$82.15M–
FY2020Dec 31, 2020-$66.35M–
FY2019Dec 31, 2019-$27.10M–
FY2018Dec 31, 2018-$13.51M–
FY2017Dec 31, 2017-$2.20M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$6.10M–
Q1 FY2026Mar 31, 2026-$11.81M–
Q4 FY2025Dec 31, 2025-$14.21M–
Q3 FY2025Sep 30, 2025-$18.79M–
Q2 FY2025Jun 30, 2025-$12.58M–
Q1 FY2025Mar 31, 2025-$12.04M–
Q4 FY2024Dec 31, 2024-$14.81M–
Q3 FY2024Sep 30, 2024-$16.34M–
Q2 FY2024Jun 30, 2024-$23.17M–
Q1 FY2024Mar 31, 2024-$17.71M–
Q4 FY2023Dec 31, 2023-$26.86M–
Q3 FY2023Sep 30, 2023-$37.58M–
Q2 FY2023Jun 30, 2023-$38.21M–
Q1 FY2023Mar 31, 2023-$52.35M–
Q4 FY2022Dec 31, 2022-$38.64M–
Q3 FY2022Sep 30, 2022-$31.19M–
Q2 FY2022Jun 30, 2022-$33.10M–
Q1 FY2022Mar 31, 2022-$32.41M–
Q4 FY2021Dec 31, 2021-$19.93M–
Q3 FY2021Sep 30, 2021-$20.20M–
Q2 FY2021Jun 30, 2021-$22.38M–
Q1 FY2021Mar 31, 2021-$19.64M–
Q4 FY2020Dec 31, 2020-$20.27M–
Q3 FY2020Sep 30, 2020-$19.10M–
Q2 FY2020Jun 30, 2020-$14.82M–
Q1 FY2020Mar 31, 2020-$12.16M–
Q4 FY2019Dec 31, 2019-$7.92M–
Q3 FY2019Sep 30, 2019-$7.49M–
Q2 FY2019Jun 30, 2019-$6.03M–
Q1 FY2019Mar 31, 2019-$5.67M–
Q4 FY2018Dec 31, 2018-$4.34M–
Q3 FY2018Sep 30, 2018-$3.19M–
Q2 FY2018Jun 30, 2018-$4.97M–
Q1 FY2018Mar 31, 2018-$1.01M–
Q4 FY2017Dec 31, 2017-$1.10M–
Q3 FY2017Sep 30, 2017-$322.00K–
Q2 FY2017Jun 30, 2017-$345.00K–
Q1 FY2017Mar 31, 2017-$431.00K–

More BioXcel Therapeutics figures

See a number that looks wrong?